MA55091A - Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab - Google Patents

Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab

Info

Publication number
MA55091A
MA55091A MA055091A MA55091A MA55091A MA 55091 A MA55091 A MA 55091A MA 055091 A MA055091 A MA 055091A MA 55091 A MA55091 A MA 55091A MA 55091 A MA55091 A MA 55091A
Authority
MA
Morocco
Prior art keywords
pembrolizumab
cancer therapy
disubstituted benzene
alkynyl compound
alkynyl
Prior art date
Application number
MA055091A
Other languages
English (en)
Inventor
Hiroshi Hirai
Kazuaki Matsuoka
Kazuhiko Yonekura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA55091A publication Critical patent/MA55091A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055091A 2019-02-28 2020-02-28 Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab MA55091A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019035603 2019-02-28
JP2019112619 2019-06-18

Publications (1)

Publication Number Publication Date
MA55091A true MA55091A (fr) 2022-01-05

Family

ID=72239799

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055088A MA55088A (fr) 2019-02-28 2020-02-28 Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire
MA055091A MA55091A (fr) 2019-02-28 2020-02-28 Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA055088A MA55088A (fr) 2019-02-28 2020-02-28 Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire

Country Status (8)

Country Link
US (2) US20220125793A1 (fr)
EP (2) EP3932425A4 (fr)
JP (6) JPWO2020175704A1 (fr)
KR (2) KR20210131387A (fr)
AU (4) AU2020228514B2 (fr)
MA (2) MA55088A (fr)
TW (2) TW202045182A (fr)
WO (2) WO2020175697A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (fr) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. Préparation et composition de traitement de tumeurs malignes
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
EP4034118A1 (fr) * 2019-09-26 2022-08-03 Janssen Pharmaceutica NV Utilisation d'inhibiteurs de fgfr dans des cancers génétiquement modifiés par fgfr pour améliorer la réponse du patient à des inhibiteurs du point de contrôle immunitaire dans des conditions de traitement séquentiel
WO2025046272A1 (fr) 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Méthodes de traitement du cancer à l'aide de futibatinib et de pembrolizumab

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
MY171055A (en) * 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
KR101480809B1 (ko) 2012-03-26 2015-01-09 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
JP6572561B2 (ja) 2015-03-03 2019-09-11 ダイキン工業株式会社 熱交換器および空気調和機
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2018006181A (es) * 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
JP6409797B2 (ja) 2016-02-24 2018-10-24 三菱電機株式会社 冷蔵庫
EP3424505A4 (fr) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. Préparation et composition de traitement de tumeurs malignes

Also Published As

Publication number Publication date
KR20210131387A (ko) 2021-11-02
US20220184082A1 (en) 2022-06-16
JPWO2020175697A1 (fr) 2020-09-03
JP2023096156A (ja) 2023-07-06
AU2020228514A1 (en) 2021-10-07
AU2025203865A1 (en) 2025-06-19
AU2020228514B2 (en) 2025-02-27
JP2023112136A (ja) 2023-08-10
EP3932425A1 (fr) 2022-01-05
TW202045182A (zh) 2020-12-16
JP2024152860A (ja) 2024-10-25
EP3932427A1 (fr) 2022-01-05
WO2020175697A1 (fr) 2020-09-03
AU2020229714A1 (en) 2021-10-07
EP3932427A4 (fr) 2022-12-07
EP3932425A4 (fr) 2022-12-07
US20220125793A1 (en) 2022-04-28
JPWO2020175704A1 (fr) 2020-09-03
TW202039507A (zh) 2020-11-01
AU2025203861A1 (en) 2025-06-19
WO2020175704A1 (fr) 2020-09-03
AU2020229714B2 (en) 2025-02-27
KR20210130774A (ko) 2021-11-01
MA55088A (fr) 2022-01-05
JP2025075059A (ja) 2025-05-14

Similar Documents

Publication Publication Date Title
MA55091A (fr) Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab
MA55587A (fr) Composés diazine-amide à action pesticide
MA53008A (fr) Composés azole-amide à action pesticide
EP3810885A4 (fr) Échelles combinées, composants d'échelle et procédés associés
MA46793A (fr) Polythérapies faisant appel à un inhibiteur d'arginase
EP3838899A4 (fr) Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, et utilisation associée
EP3766892A4 (fr) Composé de bismuth, composition durcissable et produit durci
EP3946524A4 (fr) Ensemble d'injection à manchon mobile
IL280266A (en) Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer
EP3792299A4 (fr) Film de résine polyamide, et stratifié de résine faisant appel à celui-ci
EP4063372A4 (fr) Composé et biomatériau marqué par fluorescence le comprenant
EP3514146A4 (fr) Composé de diaryl azole et pesticide
EP3808747A4 (fr) Composé d'imidazopyridinone
EP3722395A4 (fr) Composé inhibant le frottement, et composition inhibant le frottement comprenant celui-ci
EP3778563A4 (fr) Composé de phénoxy urée et agent de lutte antiparasitaire
EP4004074A4 (fr) Composition de polyuréthane à émission d'aldéhyde réduite
EP4034052A4 (fr) Ensemble doigt biomédical avec verrou à cliquet
EP3686186A4 (fr) Composé, composition de revêtement le comprenant, et diode électroluminescente organique
EP4180433A4 (fr) Composé triazine, composition et utilisation associées
EP3901147A4 (fr) Composé hétérocyclique à pont acylamino, composition et utilisation associées
EP3618578A4 (fr) Composition et élément électroluminescent faisant appel à ladite composition
EP4442717A4 (fr) Gel polymère à haute viscosité et haute résistance
EP4253386A4 (fr) Composé thiénopyridone modifié au deutérium
EP3972566A4 (fr) Microsphères radiothérapeutiques
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical